Compare TOP & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOP | PRLD |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 529.1M |
| IPO Year | 2021 | 2020 |
| Metric | TOP | PRLD |
|---|---|---|
| Price | $15.54 | $4.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 109.9K | ★ 518.4K |
| Earning Date | 01-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.25 | 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | $4,723,765.00 | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 41.89 | ★ 73.43 |
| 52 Week Low | $0.61 | $0.99 |
| 52 Week High | $17.42 | $6.83 |
| Indicator | TOP | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 66.86 | 42.51 |
| Support Level | $14.34 | $3.92 |
| Resistance Level | $17.42 | $5.34 |
| Average True Range (ATR) | 1.04 | 0.34 |
| MACD | -0.35 | -0.13 |
| Stochastic Oscillator | 47.80 | 26.71 |
TOP Financial Group Ltd is operates as an online brokerage firm in Hong Kong specializing in the trading of local and overseas equities, futures, and options products. It conduct the futures and stock brokerage business through three trading platforms, Esunny for futures trading and Longbridge for stock trading, all of which were licensed from third parties and can be easily accessed through its application, or APP, software, and websites. The three platforms are designed for seamless, efficient, and secure trading platform. The company operates and manages its business as a single operating and reportable segment.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.